acetazolamide has been researched along with Weight Loss in 26 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Currently, no standardized treatment guidelines are available and the current management focuses on weight loss and acetazolamide use." | 9.41 | Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: A literature review. ( Goyal, A; Zarroli, K, 2023) |
| "Patients underwent weight loss and treatment with acetazolamide during a 24-week period." | 9.08 | The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri) ( Johnson, LN; Krohel, GB; Madsen, RW; March, GA, 1998) |
| "Acetazolamide (ACZ) lowers intraocular pressure (IOP), acutely in normal eyes and both acutely and chronically in eyes with glaucoma, and cerebrospinal fluid pressure (CSFp), chronically in patients with idiopathic intracranial hypertension (IIH)." | 7.91 | The Effect of Acetazolamide and Weight Loss on Intraocular Pressure in Idiopathic Intracranial Hypertension Patients. ( Banik, R; Garvin, MK; Kupersmith, MJ; Wang, JK, 2019) |
| " Currently, no standardized treatment guidelines are available and the current management focuses on weight loss and acetazolamide use." | 5.41 | Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: A literature review. ( Goyal, A; Zarroli, K, 2023) |
| " The Idiopathic Intracranial Hypertension Treatment Trial, a large, randomized, collaborative clinical trial, evaluated the efficacy of acetazolamide with weight loss versus placebo with weight loss in participants." | 5.22 | Pseudotumor cerebri: What We Have Learned from the Idiopathic Intracranial Hypertension Treatment Trial. ( Johnson, LN; Johnson, MA; Krohel, GB; Thakore, RV, 2016) |
| "To assess treatment efficacy using spectral-domain (SD) optical coherence tomography (OCT) measurements of papilledema in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), which evaluated the effects of acetazolamide and weight management and of placebo and weight management in eyes with mild visual loss." | 5.20 | Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial. ( , 2015) |
| " The Idiopathic Intracranial Hypertension Treatment Trial was an adult, multicenter study that examined the use of acetazolamide and weight loss on the course of PIH." | 5.12 | Pediatric Intracranial Hypertension: A Spotlight on Imaging, the Idiopathic Intracranial Hypertension Treatment Trial, and COVID-19 Associated Cases. ( Aylward, SC; Brun, BN, 2021) |
| "Patients underwent weight loss and treatment with acetazolamide during a 24-week period." | 5.08 | The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri) ( Johnson, LN; Krohel, GB; Madsen, RW; March, GA, 1998) |
| " Both completed trials compared acetazolamide to placebo, in conjunction with a weight loss intervention in both groups." | 4.91 | Interventions for idiopathic intracranial hypertension. ( Fouyas, IP; Hughes, MA; Jamjoom, AA; Kalyvas, AV; Piper, RJ; Young, AM, 2015) |
| " Treatment options are serial lumbar punctures combined with body weight reduction as well as medication with carbonic anhydrase inhibitors, such as acetazolamide and topiramate or diuretic therapy with furosemide." | 4.91 | [Characteristic neurological features, differential diagnostic criteria and medicinal treatment of idiopathic intracranial hypertension]. ( Nacimiento, W; Willenborg, KD, 2015) |
| "This open-label, single-center pilot study suggests that GLP-1-RAs are an effective and safe treatment option for achieving significant weight loss with a favorable effect on headache, leading to reduced acetazolamide dosage in pwIIH." | 4.31 | Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. ( Bsteh, G; Harreiter, J; Itariu, B; Krajnc, N; Macher, S; Marik, W; Michl, M; Novak, K; Pemp, B; Wöber, C, 2023) |
| "Acetazolamide (ACZ) lowers intraocular pressure (IOP), acutely in normal eyes and both acutely and chronically in eyes with glaucoma, and cerebrospinal fluid pressure (CSFp), chronically in patients with idiopathic intracranial hypertension (IIH)." | 3.91 | The Effect of Acetazolamide and Weight Loss on Intraocular Pressure in Idiopathic Intracranial Hypertension Patients. ( Banik, R; Garvin, MK; Kupersmith, MJ; Wang, JK, 2019) |
| " One child with PTC demonstrated improvement in visual acuity and optic nerve appearance after acetazolamide and weight loss therapy." | 3.74 | Pseudotumor cerebri in children with Down syndrome. ( Bradfield, YS; Esmaili, N, 2007) |
| " This was managed non-operatively with lumbar cerebrospinal fluid tap, weight reduction, nicotinic acid and acetazolamide." | 3.73 | Non-operative management of benign intracranial hypertension presenting with complete visual loss and deafness. ( Idowu, OE; Malomo, AO; Nwaorgu, OG; Oluleye, TS; Shokunbi, MT, 2006) |
| "Prominent weight loss was recorded in the topiramate group." | 2.73 | Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. ( Akyürekli, O; Celebisoy, N; Gökçay, F; Sirin, H, 2007) |
| "Some theories - such as the dural sinus stenosis theory - seem to ignore the relationship with weight gain; others have proposed a direct link between obesity and raised intracranial pressure through a specific fat distribution in the body; others through the production of lipokines; and yet others have suggested a converse causation with raised intracranial pressure giving rise to obesity." | 2.47 | The syndrome of pseudotumour cerebri and idiopathic intracranial hypertension. ( Fraser, C; Plant, GT, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (23.08) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Brun, BN | 1 |
| Aylward, SC | 1 |
| Krajnc, N | 1 |
| Itariu, B | 1 |
| Macher, S | 1 |
| Marik, W | 1 |
| Harreiter, J | 1 |
| Michl, M | 1 |
| Novak, K | 1 |
| Wöber, C | 1 |
| Pemp, B | 1 |
| Bsteh, G | 1 |
| Goyal, A | 1 |
| Zarroli, K | 1 |
| Ybarra, M | 1 |
| Santos, TJD | 1 |
| Queiroz, ES | 1 |
| Rachid, L | 1 |
| Franco, RR | 1 |
| Cominato, L | 1 |
| Moura, FC | 1 |
| Velhote, MC | 1 |
| Damiani, D | 1 |
| Raggi, A | 1 |
| Grazzi, L | 1 |
| Bianchi Marzoli, S | 1 |
| Ciasca, P | 1 |
| Chiapparini, L | 1 |
| Erbetta, A | 1 |
| Faragò, G | 1 |
| Leonardi, M | 1 |
| D'Amico, D | 1 |
| Núñez, J | 1 |
| Heredia, R | 1 |
| Payá, A | 1 |
| Sanchis, I | 1 |
| Del Prado, S | 1 |
| Miñana, G | 1 |
| Santas, E | 1 |
| de la Espriella, R | 1 |
| Núñez, E | 1 |
| Sanchis, J | 1 |
| Bayés-Genís, A | 1 |
| Banik, R | 1 |
| Kupersmith, MJ | 1 |
| Wang, JK | 1 |
| Garvin, MK | 1 |
| Piper, RJ | 1 |
| Kalyvas, AV | 1 |
| Young, AM | 1 |
| Hughes, MA | 1 |
| Jamjoom, AA | 1 |
| Fouyas, IP | 1 |
| Willenborg, KD | 1 |
| Nacimiento, W | 1 |
| Thakore, RV | 1 |
| Johnson, MA | 1 |
| Krohel, GB | 2 |
| Johnson, LN | 2 |
| Wall, M | 1 |
| Thurtell, MJ | 1 |
| Landau, K | 1 |
| Skau, M | 1 |
| Sander, B | 1 |
| Milea, D | 1 |
| Jensen, R | 1 |
| Fraser, C | 1 |
| Plant, GT | 1 |
| Belliveau, MJ | 1 |
| ten Hove, MW | 1 |
| Mathews, MK | 1 |
| Sergott, RC | 1 |
| Savino, PJ | 1 |
| Malomo, AO | 1 |
| Idowu, OE | 1 |
| Shokunbi, MT | 1 |
| Nwaorgu, OG | 1 |
| Oluleye, TS | 1 |
| Esmaili, N | 1 |
| Bradfield, YS | 1 |
| Celebisoy, N | 1 |
| Gökçay, F | 1 |
| Sirin, H | 1 |
| Akyürekli, O | 1 |
| Kuriyama, T | 2 |
| Atherton, DJ | 1 |
| Rustin, MH | 1 |
| Brostoff, J | 1 |
| Madsen, RW | 1 |
| March, GA | 1 |
| Pomeranz, HD | 1 |
| McIlwaine, G | 1 |
| Lueck, C | 1 |
| Chin, K | 1 |
| Ohi, M | 1 |
| Fukui, M | 1 |
| Hirai, M | 1 |
| Kuno, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss[NCT01003639] | Phase 2/Phase 3 | 165 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Treatment Effects on the Primary Outcome Variable, Mean change From Baseline to Month 6 in Perimetric Mean Deviation (PMD) in the Study Eye. Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to -32 dB; larger negative values indicate greater vision loss. (NCT01003639)
Timeframe: base line and 6 months
| Intervention | dB (Mean) |
|---|---|
| Acetazolamide | 1.43 |
| Sugar Pill | 0.71 |
Mean change at month 6 as compared to baseline. Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema. (NCT01003639)
Timeframe: Baseline and 6 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Study eye | Fellow eye | |
| Acetazolamide | -1.31 | -1.14 |
| Sugar Pill | -0.61 | -0.52 |
(NCT01003639)
Timeframe: Baseline
| Intervention | correct letters (Mean) | |
|---|---|---|
| Study Eye | Fellow Eye | |
| Acetazolamide | 56.8 | 58.3 |
| Sugar Pill | 55.6 | 56.2 |
Visual Function Questionnaire (VFQ-25) total score, VFQ-25 10-item neuro-ophthalmic supplement total score: 0-100 (higher scores indicate better quality of life) (NCT01003639)
Timeframe: baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Total score | 10-item neuro-ophthalmic supplement | |
| Acetazolamide | 83.8 | 75.8 |
| Sugar Pill | 82.1 | 75.0 |
7 reviews available for acetazolamide and Weight Loss
| Article | Year |
|---|---|
Pediatric Intracranial Hypertension: A Spotlight on Imaging, the Idiopathic Intracranial Hypertension Treatment Trial, and COVID-19 Associated Cases.
Topics: Acetazolamide; Adolescent; Adult; Carbonic Anhydrase Inhibitors; Child; Combined Modality Therapy; C | 2021 |
Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: A literature review.
Topics: Acetazolamide; Female; Headache; Humans; Intracranial Hypertension; Intracranial Pressure; Pseudotum | 2023 |
Interventions for idiopathic intracranial hypertension.
Topics: Acetazolamide; Adult; Antihypertensive Agents; Cerebrospinal Fluid Pressure; Female; Headache; Human | 2015 |
[Characteristic neurological features, differential diagnostic criteria and medicinal treatment of idiopathic intracranial hypertension].
Topics: Acetazolamide; Cerebrospinal Fluid Shunts; Combined Modality Therapy; Diagnosis, Differential; Fruct | 2015 |
[Neuro-ophthalmology essentials].
Topics: Acetazolamide; Adrenal Cortex Hormones; Adult; Aged; Blepharoptosis; Carbonic Anhydrase Inhibitors; | 2009 |
The syndrome of pseudotumour cerebri and idiopathic intracranial hypertension.
Topics: Acetazolamide; Body Mass Index; Carbonic Anhydrase Inhibitors; Constriction, Pathologic; Humans; Int | 2011 |
Pseudotumor cerebri.
Topics: Acetazolamide; Adrenal Cortex Hormones; Carbonic Anhydrase Inhibitors; Diagnosis, Differential; Huma | 2003 |
6 trials available for acetazolamide and Weight Loss
| Article | Year |
|---|---|
Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.
Topics: Acetazolamide; Carbonic Anhydrase Inhibitors; Double-Blind Method; Follow-Up Studies; Humans; Nerve | 2015 |
Pseudotumor cerebri: What We Have Learned from the Idiopathic Intracranial Hypertension Treatment Trial.
Topics: Acetazolamide; Adolescent; Adult; Diuretics; Female; Humans; Male; Middle Aged; North America; Obesi | 2016 |
Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial.
Topics: Acetazolamide; Adult; Carbonic Anhydrase Inhibitors; Cerebrospinal Fluid Pressure; Combined Modality | 2017 |
Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study.
Topics: Acetazolamide; Adult; Body Mass Index; Diuretics; Female; Follow-Up Studies; Humans; Male; Papillede | 2011 |
Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.
Topics: Acetazolamide; Adolescent; Adult; Anticonvulsants; Body Weight; Carbonic Anhydrase Inhibitors; Cereb | 2007 |
The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)
Topics: Acetazolamide; Adult; Body Mass Index; Body Weight; Female; Humans; Middle Aged; Obesity; Papilledem | 1998 |
13 other studies available for acetazolamide and Weight Loss
| Article | Year |
|---|---|
Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension.
Topics: Acetazolamide; Adult; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Headache; H | 2023 |
BARIATRIC SURGERY AS A TREATMENT FOR IDIOPATHIC INTRACRANIAL HYPERTENSION IN A MALE ADOLESCENT: CASE REPORT.
Topics: Acetazolamide; Adolescent; Aftercare; Bariatric Surgery; Diuretics; Fundus Oculi; Headache; Humans; | 2020 |
The importance of specific rehabilitation for an obese patient with idiopathic intracranial hypertension: a case report.
Topics: Acetazolamide; Adult; Carbonic Anhydrase Inhibitors; Diet, Reducing; Female; Humans; Obesity; Papill | 2018 |
Use of acetazolamide in the treatment of patients with refractory congestive heart failure.
Topics: Acetazolamide; Administration, Oral; Aged; Aged, 80 and over; Biomarkers; CA-125 Antigen; Diuretics; | 2018 |
The Effect of Acetazolamide and Weight Loss on Intraocular Pressure in Idiopathic Intracranial Hypertension Patients.
Topics: Acetazolamide; Adolescent; Adult; Carbonic Anhydrase Inhibitors; Cerebrospinal Fluid Pressure; Femal | 2019 |
Idiopathic intracranial hypertension.
Topics: Acetazolamide; Anti-Bacterial Agents; Antidepressive Agents; Body Mass Index; Cerebrospinal Fluid Sh | 2011 |
Non-operative management of benign intracranial hypertension presenting with complete visual loss and deafness.
Topics: Acetazolamide; Adolescent; Blindness; Deafness; Diuretics; Female; Humans; Niacin; Pseudotumor Cereb | 2006 |
Pseudotumor cerebri in children with Down syndrome.
Topics: Acetazolamide; Child; Child, Preschool; Diuretics; Down Syndrome; Female; Humans; Intracranial Press | 2007 |
Symposium on clinical aspects of sleep-disordered breathing and circulation. Treatment.
Topics: Acetazolamide; Clinical Protocols; Dental Prosthesis; Drug Therapy, Combination; Humans; Progesteron | 1995 |
Need for correct identification of herbs in herbal poisoning.
Topics: Acetazolamide; Drug Combinations; Drug Contamination; Drug Interactions; Drugs, Chinese Herbal; Huma | 1993 |
Weight loss, acetazolamide, and pseudotumor cerebri.
Topics: Acetazolamide; Body Weight; Humans; Obesity; Papilledema; Pseudotumor Cerebri; Weight Loss | 1999 |
Weight loss in idiopathic intracranial hypertension.
Topics: Acetazolamide; Diuretics; Humans; Intracranial Hypertension; Papilledema; Weight Loss | 1999 |
[Therapy and clinical symptoms in patients with obstructive sleep apnea in Japan].
Topics: Accidents, Traffic; Acetazolamide; Adult; Humans; Japan; Middle Aged; Positive-Pressure Respiration; | 1992 |